Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

MERIC-BERNSTAM, FUNDA

One or more keywords matched the following items that are connected to MERIC-BERNSTAM, FUNDA

Item Type	Name
Academic Article	Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Concept	Sirolimus
Academic Article	Determinants of rapamycin sensitivity in breast cancer cells.
Academic Article	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
Academic Article	Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy.
Academic Article	Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Academic Article	Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.
Academic Article	Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
Academic Article	Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
Academic Article	Targeting the mTOR signaling network for cancer therapy.
Academic Article	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Academic Article	Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.
Academic Article	Mammalian target of rapamycin.
Academic Article	Rapamycin regulates the phosphorylation of rictor.
Academic Article	Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.
Academic Article	The rapamycin-regulated gene expression signature determines prognosis for breast cancer.
Academic Article	Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer.
Academic Article	Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
Academic Article	Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.
Academic Article	Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?.
Academic Article	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
Academic Article	Epithelial to mesenchymal transition is associated with rapamycin resistance.
Academic Article	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Academic Article	Epithelial to mesenchymal transition is associated with rapamycin resistance
Academic Article	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Academic Article	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Academic Article	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Academic Article	Rapamycin?-?mTOR?+?BRAF?=?? Using relational similarity to find therapeutically relevant drug-gene relationships in unstructured text.
Concept	Mechanistic Target of Rapamycin Complex 1
Concept	Mechanistic Target of Rapamycin Complex 2
Concept	Rapamycin-Insensitive Companion of mTOR Protein
Academic Article	Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation.
Academic Article	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.
Academic Article	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Academic Article	Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
Academic Article	Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Academic Article	Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.

Search Criteria

Sirolimus